Johnson & Johnson Announces Darren Snellgrove as Vice President, Investor Relations
Johnson & Johnson (NYSE: JNJ) has announced key leadership changes effective May 1, 2025. Darren Snellgrove has been appointed as Vice President of Investor Relations, while Jessica Moore will transition to the role of Group Chief Financial Officer for Johnson & Johnson's Innovative Medicine division.
Snellgrove, who brings 25 years of financial leadership experience across Innovative Medicine, MedTech, R&D, and Business Development, most recently served as Group CFO for Innovative Medicine. He joined the company in 1999 and holds a bachelor's degree from Southampton University and an MBA from Villanova University.
Moore, who has led Investor Relations since 2021, will take on her new role in the Innovative Medicine business. Both executives will continue reporting to Executive Vice President and CFO Joseph Wolk.
Johnson & Johnson (NYSE: JNJ) ha annunciato importanti cambiamenti nella leadership a partire dal 1 maggio 2025. Darren Snellgrove è stato nominato Vicepresidente delle Relazioni con gli Investitori, mentre Jessica Moore passerà al ruolo di Chief Financial Officer del Gruppo per la divisione Innovative Medicine di Johnson & Johnson.
Snellgrove, che porta con sé 25 anni di esperienza nella leadership finanziaria in Innovative Medicine, MedTech, R&D e Sviluppo Aziendale, ha recentemente ricoperto il ruolo di CFO del Gruppo per Innovative Medicine. È entrato in azienda nel 1999 e ha conseguito una laurea presso l'Università di Southampton e un MBA presso l'Università di Villanova.
Moore, che ha guidato le Relazioni con gli Investitori dal 2021, assumerà il suo nuovo ruolo nel business di Innovative Medicine. Entrambi i dirigenti continueranno a riferire al Vicepresidente Esecutivo e CFO Joseph Wolk.
Johnson & Johnson (NYSE: JNJ) ha anunciado cambios clave en el liderazgo que entrarán en vigor el 1 de mayo de 2025. Darren Snellgrove ha sido nombrado Vicepresidente de Relaciones con Inversores, mientras que Jessica Moore pasará al cargo de Directora Financiera del Grupo para la división de Medicinas Innovadoras de Johnson & Johnson.
Snellgrove, quien aporta 25 años de experiencia en liderazgo financiero en Medicinas Innovadoras, MedTech, I+D y Desarrollo de Negocios, se desempeñó recientemente como CFO del Grupo para Medicinas Innovadoras. Se unió a la empresa en 1999 y tiene una licenciatura de la Universidad de Southampton y un MBA de la Universidad de Villanova.
Moore, quien ha liderado Relaciones con Inversores desde 2021, asumirá su nuevo rol en el negocio de Medicinas Innovadoras. Ambos ejecutivos continuarán reportando al Vicepresidente Ejecutivo y CFO Joseph Wolk.
존슨앤존슨 (NYSE: JNJ)은 2025년 5월 1일부터 시행되는 주요 리더십 변화를 발표했습니다. 다렌 스넬그로브가 투자자 관계 부사장으로 임명되었으며, 제시카 무어는 존슨앤존슨의 혁신 의학 부서의 그룹 최고 재무 책임자로 전환됩니다.
스넬그로브는 혁신 의학, 메드테크, 연구개발 및 비즈니스 개발 분야에서 25년의 재무 리더십 경험을 가지고 있으며, 최근에는 혁신 의학 부서의 그룹 CFO로 재직했습니다. 그는 1999년에 회사에 합류했으며, 사우샘프턴 대학교에서 학사 학위를, 빌라노바 대학교에서 MBA를 받았습니다.
무어는 2021년부터 투자자 관계를 이끌어 왔으며, 혁신 의학 사업에서 새로운 역할을 맡게 됩니다. 두 임원 모두 부사장 겸 CFO인 조셉 월크에게 계속 보고할 것입니다.
Johnson & Johnson (NYSE: JNJ) a annoncé des changements clés dans la direction à compter du 1er mai 2025. Darren Snellgrove a été nommé Vice-président des Relations avec les Investisseurs, tandis que Jessica Moore passera au poste de Directrice Financière du Groupe pour la division des Médicaments Innovants de Johnson & Johnson.
Snellgrove, qui apporte 25 ans d'expérience en leadership financier dans les domaines des Médicaments Innovants, MedTech, R&D et Développement Commercial, a récemment occupé le poste de CFO du Groupe pour les Médicaments Innovants. Il a rejoint l'entreprise en 1999 et détient un diplôme de premier cycle de l'Université de Southampton et un MBA de l'Université de Villanova.
Moore, qui dirige les Relations avec les Investisseurs depuis 2021, assumera son nouveau rôle dans le secteur des Médicaments Innovants. Les deux dirigeants continueront de rendre compte au Vice-président Exécutif et CFO Joseph Wolk.
Johnson & Johnson (NYSE: JNJ) hat zum 1. Mai 2025 wichtige Veränderungen in der Führung angekündigt. Darren Snellgrove wurde zum Vizepräsidenten für Investor Relations ernannt, während Jessica Moore die Rolle der Gruppen-CFO für die Innovative Medicine-Sparte von Johnson & Johnson übernehmen wird.
Snellgrove bringt 25 Jahre Erfahrung in der finanziellen Führung in den Bereichen Innovative Medicine, MedTech, F&E und Geschäftsentwicklung mit und war zuletzt Gruppen-CFO für Innovative Medicine. Er trat 1999 in das Unternehmen ein und hat einen Bachelor-Abschluss von der Universität Southampton sowie einen MBA von der Villanova University.
Moore, die seit 2021 die Investor Relations leitet, wird ihre neue Rolle im Bereich Innovative Medicine übernehmen. Beide Führungskräfte werden weiterhin an den Executive Vice President und CFO Joseph Wolk berichten.
- Internal promotion demonstrates strong leadership pipeline
- Seamless transition with both executives reporting to CFO
- Appointment of experienced leader with 25 years financial expertise
- None.
Jessica Moore Appointed Group Chief Financial Officer, Johnson & Johnson, Innovative Medicine
“Today’s announcement reflects the deep bench of talent within Johnson & Johnson as well as our commitment to fostering career paths for leaders within the Company,” said Mr. Wolk, “Darren’s depth and breadth of experience across Johnson & Johnson provides a strong foundation for his new role engaging with analysts and investors and helping them understand our long-term strategy, governance and compelling value proposition.”
Mr. Snellgrove brings 25 years of strong and broad financial leadership spanning across Innovative Medicine, MedTech, R&D, and Business Development positions. He most recently served as the Group Chief Financial Officer for Innovative Medicine where he has played a critical role in the financial leadership and analysis of Johnson & Johnson’s Innovative Medicine business, delivering above-market growth while prioritizing investment in future innovation. Mr. Snellgrove has also served as Vice President, Finance for Innovative Medicine R&D and Vice President, Finance for Johnson & Johnson Innovation and Pharmaceutical Business Development.
Mr. Snellgrove joined Johnson & Johnson in 1999. He holds a bachelor’s honors degree in economics and philosophy from
“Jessica’s strong leadership of the Investor Relations team over the last three years, along with her substantive financial expertise, will make her an excellent finance leader for our Innovative Medicine business,” added Mr. Wolk.
About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at https://www.jnj.com. Follow us at @JNJNews and on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250304349289/en/
Media contact:
media-relations@its.jnj.com
Investor contact:
investor-relations@its.jnj.com
Source: Johnson & Johnson
FAQ
When will Darren Snellgrove start as VP of Investor Relations at JNJ?
What is Darren Snellgrove's background and experience at JNJ?
Who is replacing Jessica Moore in JNJ's Investor Relations role?
What new role will Jessica Moore take at JNJ?
